REGEND001

Idiopathic Pulmonary Fibrosis

Clinical trials

Developer

Regend Therapeutics

Overview

REGEND001 is an agent tracked by PF-Atlas in the context of idiopathic pulmonary fibrosis. It appears in 2 tracked IPF clinical trials.

REGEND001 clinical trials

NCT05657184 (Phase 1)NCT06081621 (Phase 2)

Explore related

All trials Research

Medical disclaimer. This page summarizes research about REGEND001 for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.